<DOC>
	<DOCNO>NCT02064842</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics TMC647055 combination ritonavir ( Part 1 ) ; potential pharmacokinetic drug-drug interaction TMC435 combination TMC647055 ritonavir ; evaluate short-term safety tolerability TMC435 , TMC647055 Ritonavir co-administered ( Part 2 ) healthy Japanese participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics TMC647055 Combination With Ritonavir ( Part 1 ) Co-administration TMC435 , TMC647055 Ritonavir ( Part 2 ) Healthy Japanese Participants</brief_title>
	<detailed_description>This single-center study consist 2 part , sequentially conduct 2 separate panel 24 healthy adult Japanese participant . Part 1 double-blinded ( neither physician participant know treatment participant receives ) , placebo-controlled ( placebo compare study medication test whether study medication real effect clinical study ) , randomize ( study medication assign chance ) single ascend dose ( SAD ) part consist screen phase , treatment phase , follow-up visit . Part 1 3 cohort ( Cohort A , B , C ) 8 participant randomly assign receive either single oral dose TMC647055 ( 6 participant ) placebo ( 2 participant ) combination RTV . The study duration participant approximately 5 week screen follow-up visit maximum Part 1 . Part 2 open-label , randomize , 3-way crossover part consist screen phase , 3 treatment phase , follow-up phase . Each 24 participant receive Treatment A , B , C 6 sequence ( Treatment ABC , BCA , CAB , ACB , BAC , CBA ) washout period least 7 day consecutive treatment . Safety evaluation include assessment adverse event , clinical laboratory test , vital sign , electrocardiogram , physical examination . The study duration participant approximately 10 week screen follow-up visit maximum .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Man woman Japanese descent reside outside Japan 5 year whose parent grandparents Japanese determine participant 's verbal report Must sign informed consent form Women must nonchildbearing potential ( postmenopausal least 2 year , surgically sterile , otherwise incapable become pregnant ) Women , except postmenopausal woman , negative serum bhuman chorionic gonadotropin pregnancy test screen Men heterosexually active woman childbearing potential must agree use two effective method birth control , men must also donate sperm study 3 month receive last dose study medication Must body mass index 16.0 30.0 kg/m2 , inclusive , body weight less 45 kg screen History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use within past 1 year Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participant 's Hepatitis A , B , C infection , human immunodeficiency virus type 1 2 ( HIV1 HIV2 ) infection study screen Female participant breastfeed screen History liver renal impairment , significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , neoplastic , metabolic disturbance History clinically relevant skin disease history allergy medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>TMC647055</keyword>
	<keyword>TMC435</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Sovriad</keyword>
	<keyword>Ritonavir ( RTV )</keyword>
</DOC>